Physicians Use Cardioscan to Evaluate Student Athletes During Sports Physicals
February 20 2008 - 12:46PM
PR Newswire (US)
PRINCETON, N.J., Feb. 20 /PRNewswire/ -- Zargis Medical Corp., a
spin-off from Siemens Corporate Research (NYSE:SI) and a
majority-owned subsidiary of Speedus Corp. (NASDAQ:SPDE) today
announced that Cardioscan(R) is being used at the middle and high
schools in Long Branch, New Jersey to evaluate student athletes
during preparticipation sports physicals. The Cardioscan evaluation
is being undertaken in conjunction with The Children's Hospital at
Monmouth Medical Center in Long Branch, which provides school
physicians for the district. The school nurses for the district
have been actively administering Cardioscan to athletes and the
results are being interpreted by physicians. Following the
conclusion of the program, which will involve nearly 800 students
over the next 12 months, the Center's Director of Pediatric
Inpatient Services, Dr. Richard DeGroote, and Dr. Rhea Salonga,
will interpret the findings and intend to submit the results for
publication. According to Dr. DeGroote, "There is clearly a need
for a cost-effective screening method which could be an adjunct to
the preparticipation sports physical exam in the early
identification of certain potentially lethal cardiovascular
abnormalities in young athletes. Although rare, the death of a
young athlete from a previously undetected cardiovascular
abnormality (an event commonly referred to as Sudden Cardiac Death
or "SCD") is a tragedy that impacts an entire community and
receives a great deal of media attention. I am very pleased that
the Long Branch school district is the first school in the country
to incorporate Cardioscan into student physicals." According to
Zargis CEO John Kallassy, "Our Cardioscan device could be a cost
effective addition to any school system's sports preparticipation
screening program. As a result, we believe that Cardioscan could
one day become a standard of care in pre-sports physicals in
physicians' offices or at the more than 26,000 secondary schools in
the U.S. as well as in school systems in numerous overseas
markets." As part of the evaluation protocol, the entire nursing
team for the Long Branch district, led by head nurse Kathy Celli,
has undergone training in the use of Cardioscan. About Zargis
Medical Corp. Zargis Medical Corp. develops advanced diagnostic
decision support products and services for primary care physicians,
pediatricians, cardiologists and other healthcare professionals.
Zargis was formed in 2001 when Siemens Corporate Research, a
division of Siemens AG (NYSE:SI), and Speedus Corp. co-invested to
develop and market an advanced acoustic technology designed to
detect heart abnormalities identified through analysis of heart
sounds. About Cardioscan Zargis has developed Cardioscan, the first
and only computer-assisted medical device designed to support
physicians in analyzing heart sounds for the identification of
suspected systolic and diastolic murmurs. Cardioscan is a
non-invasive device that is easy to use, portable, and takes just
minutes to perform. The device implements voice-guided protocol and
a graphical user interface while maintaining an efficient physician
workflow. Cardioscan provides a summary of findings in terms that
are readily understood by physicians and offers an additional range
of quantitative auscultatory information that cannot be obtained
through listening alone. Cardioscan is intended to enhance
auscultation-a procedure that has been universally employed through
a stethoscope for nearly two-hundred years. The interpretations of
heart sounds offered by Cardioscan are only significant when used
in conjunction with physician over-read as well as consideration of
all other relevant patient data. For additional information about
Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext.
23) or or visit the following Web sites: http://www.zargis.com/ and
http://www.speedus.com/. Statements contained herein about Zargis
that are not historical facts, including but not limited to
statements about Zargis' product, corporate identity and focus, may
be forward-looking statements that are subject to a variety of
risks and uncertainties. There are a number of important factors
that could cause actual results to differ materially from those
expressed in any forward-looking statements made by Zargis,
including, but not limited to, the continuing development of
Zargis' sales, marketing and support efforts. Contact: Peter Hodge
Zargis 1-888-773-3669 Ext. 23 DATASOURCE: Zargis Medical Corp.
CONTACT: Peter Hodge of Zargis, +1-888-773-3669 Ext. 23, Web site:
http://www.zargis.com/ http://www.speedus.com/
Copyright
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jul 2023 to Jul 2024